Figure 3 | Scientific Reports

Figure 3

From: DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity

Figure 3

Pan-neuronal overexpression of human Tau, amyloid-β42 and mnb shortened lifespan which was partially reversible by DYRK1A inhibitor. Mantel-Cox (Log-rank) survival plots of (A) control (elav-Gal4/ +) compared to flies overexpressing: human Tau (B), human tAβ42 (C) and fly mnb (D) off drug (blue lines) compared to treated with DYR219 (red) and DYR533 (green), a rightward shift in the curve indicates an extension of life. All genotypes and treatments were performed in parallel. (E) Table showing quantification of lifespan by median survival (days) which is reduced by pan-neuronal overexpression of Tau, tAβ42 and mnb compared to elav-Gal4/ + control. DYR533 was found to be effective at extending the lifespan of all disease models while DYR219 lengthened the life of human Tau and human tAβ42 overexpressing flies (#P < 0.05 and ##P < 0.01 with n = 5 biological replicates per condition of 10 flies per replicate for all genotypes).

Back to article page